Harmony Biosciences Q3 net income falls 5% year over year to USD 48.2 million

Bitget2026/11/04 12:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Harmony Biosciences’ Q3 2026 diluted earnings per share fell 7% year-over-year to USD 0.81.
Net product revenue climbed 12% year-over-year to USD 268.9 million, supported by strong underlying WAKIX demand.
R&D expense increased 30% year-over-year to USD 71.7 million, primarily due to a USD 25 million MSN license milestone charge.
BP-205 preliminary multiple-dose results showed favorable tolerability; Phase 2 studies in multiple CNS indications are expected to begin by mid-2027.
Full-year 2026 WAKIX net revenue guidance remained USD 1 billion–USD 1.04 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Harmony Biosciences Q3 net income falls 5% year over year to USD 48.2 million

You may also like

Crypto prices